Ask VialBase
cognitive

Pinealon

Also known as: Glu-Asp-Arg, EDR peptide
Preliminary evidence FDA: Not FDA-approved WADA: Not listed

Pinealon is a synthetic neuroprotective tripeptide (Glu-Asp-Arg, "EDR") from the Khavinson Cytogen family. It is studied as a brain-targeted bioregulator that influences neuronal survival, serotonin synthesis and antioxidant defence by epigenetically regulating gene expression. In vitro and animal models report reduced free-radical damage and protection against hypoxic and homocysteine-related injury. It is not FDA-approved. For educational purposes only. Not medical advice. Pinealon is the tripeptide Glu-Asp-Arg (EDR). It is small enough to enter the cell and nucleus, and its proposed mechanism is epigenetic regulation of neuronal gene expression: 1. Gene-expression / protein-synthesis regulation. EDR has been characterised for its effect

This content is for educational and research purposes only. VialBase does not provide medical advice. Consult a healthcare professional before using any peptide.

Molecular weight 418.4 Da
Half-life ~minutes estimated;
CAS number —
Route Subcutaneous · Intranasal · Oral subcutaneous preferred
02

Mechanism

Synthetic neuroprotective tripeptide (Glu-Asp-Arg, "EDR") from the Khavinson Cytogen family. Penetrates cells and the nucleus and is proposed to act epigenetically, regulating expression of genes involved in neuronal survival, serotonin synthesis and antioxidant defence. In vitro and animal models report reduced free-radical damage, protection against hypoxia and prenatal hyperhomocysteinemia, and increased neuronal viability. Evidence is mostly cell and animal work, not FDA-grade human trials.

03

Dosing

DOSE RANGE 5–10 mg per cycle
FREQUENCY 1×/day
CYCLE LENGTH 10–20 days, repeated 2–3×/year

Short pulsed Khavinson-style cycles. Subcutaneous, intranasal and oral routes are described in practitioner protocols; no published human bioavailability data.

04

Research summary

Study Type Year Key Finding
Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes In vitro (neuronal) 2011 Pinealon increased cell viability in culture
Pinealon protects the rat offspring from prenatal hyperhomocysteinemia Animal (in vivo) 2012 Pinealon protected rat offspring against the effects of prenatal hyperhomocysteinemia
EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in Neuroprotection Molecular / mechanism 2020 Characterised how the EDR tripeptide (Pinealon) may regulate gene expression and protein synthesis
05

Stacking & interactions

Layered neuroprotection (Cytogen tripeptide + brain polypeptide complex)

Cognitive / neuroplasticity stack

Neuro + pineal/longevity protocol

06

Sourcing

Stocks this compound Third-party tested Public COAs

VialBase may earn a commission on purchases through partner links — never at additional cost to you. Full disclosure.

What bloodwork do I need?

Reference ranges are general guidelines. Consult your physician for interpretation.

PRE-CYCLE
  • CMP
  • CBC
  • Homocysteine
DURING CYCLE
  • CMP
POST-CYCLE
  • CMP
  • Homocysteine
Safety & Regulatory Status
FDA STATUS Not FDA-approved
WADA STATUS Not listed

Regulatory status for Pinealon may change. Verify current status with your jurisdiction before use. This is not legal or medical advice.

Frequently Asked Questions

What is Pinealon?
Pinealon is a synthetic neuroprotective tripeptide (Glu-Asp-Arg, "EDR") from the Khavinson Cytogen family. It is studied as a brain-targeted bioregulator that influences neuronal survival, serotonin synthesis and antioxidant defence through epigenetic regulation of gene expression.
What does the research on Pinealon show?
Pinealon (EDR) has named in vitro and animal studies: it increased cell viability by suppressing free-radical levels, protected rat offspring from prenatal hyperhomocysteinemia, and stimulated serotonin expression in brain cortex cells. Some appear in international journals. There are still no FDA-registered human trials, so the evidence tier is preliminary.
What is Pinealon's peptide sequence?
Pinealon is the tripeptide Glu-Asp-Arg (EDR), molecular weight ≈418 Da. It is the neuro-targeted member of the Khavinson Cytogens, alongside Vilon (KE), Vesugen (KED) and Epithalon.
How is Pinealon dosed?
Practitioner protocols use short pulsed courses of about 5–10 mg per cycle for 10–20 days, repeated two to three times a year, by subcutaneous, intranasal or oral routes. These are traditional Khavinson regimens, not trial-validated doses.
Is Pinealon FDA-approved?
No. Pinealon is not FDA-approved and is sold only as a research chemical. It is used within Russian bioregulatory/neurology practice. It is not prohibited by WADA. Cognitive and neuroprotective claims are not validated by controlled human trials.

References

  1. Khavinson V et al.. Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes. Rejuvenation Res (2011). PMID: 21978084
  2. Arutjunyan A et al.. Pinealon protects the rat offspring from prenatal hyperhomocysteinemia. Int J Clin Exp Med (2012). PMID: 22567179
  3. Khavinson V et al.. EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in Neuroprotection. Molecules (2020). PMID: 33396470